Bisphosphonates (pamidronate)
FDA Approved
Description
Pamidronate is a bisphosphonate that inhibits bone resorption and is used to treat various bone disorders. It has been used off-label in pediatric skeletal dysplasias and early-onset osteoarthritis to improve bone density and reduce fracture risk. The medication is administered intravenously under medical supervision.
Indications & Therapeutic Use
Paget's disease, hypercalcemia of malignancy, osteogenesis imperfecta, skeletal dysplasias
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Bisphosphonates (pamidronate)
| Generic Name | Bisphosphonates (pamidronate) |
| Brands | 1 brand available |
| Active Ingredient | Pamidronate disodium |
| Drug Class | Paget's disease |
| Manufacturer | Novartis |
| Dosage Forms | IV infusion 30mg, 60mg, 90mg vials |
| Medical Code | M05BA03 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes